Hledat klinickou studii
12 Výsledků
Studie přijímající pacienty
= 
; Probíhající studie = 
; Ukončená studie = 
; Financováno členem konsorcia IRDiRC = 
; Člen ERN = 
Národní klinické studie
NĚMECKO
Bayern
MÜNCHEN
SynCoRAS: Verbesserung der synaptischen Plastizität und der kognitiven Funktion bei Störungen des RAS-Signalweges (GeNeRARe-Studie)
TUM Fakultät für Medizin
NĚMECKO
Bayern
MÜNCHEN
SynCoRAS: Verbesserung der synaptischen Plastizität und der kognitiven Funktion bei Störungen des RAS-Signalweges (GeNeRARe-Studie)
kbo-Kinderzentrum München gemeinnützige GmbH
kbo-Kinderzentrum München
JAPONSKO
JAPAN
ADDRESS : NOT PROVIDED - JP
Pilot study of topical medicine of rapamycin for large diffuse plexiform neurofibroma of neurofibromatosis type 1
Institution: Information not provided - JP
NIZOZEMSKO
Zuid-Holland
ROTTERDAM
NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - NL
Erasmus MC - Erasmus Medisch Centrum
Afdeling Kinderneurologie
NIZOZEMSKO
Zuid-Holland
ROTTERDAM
NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - NL
Erasmus MC - Erasmus Medisch Centrum
Afdeling Neurowetenschappen
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio de fase I/II con aumento escalonado y ampliación de la dosis, multicéntrico, abierto y con un solo grupo, para evaluar la seguridad, la tolerabilidad, las características farmacocinéticas y la actividad antitumoral de FCN-159 en participantes adultos y menores de edad con neurofibromatosis de tipo 1
Institution: Information not provided - ES
ŠVÉDSKO
Region Skåne
LUND
plexifpc - Treatment of NF1-related Plexiform Neurofibroma With Trametinib; a Single Arm, Open-label Trial With the Goals of Volumetric Partial Remission and Pain Relief - SE
Skånes Universitetssjukhus
Skåne University Hospital
SPOJENÉ KRÁLOVSTVÍ
Greater London
LONDON
A Paediatric Phase I/II Study Of Intermittent Dosing Of The Mek-1 Inhibitor Selumetinib In Children With Neurofibromatosis Type-1 And Inoperable Plexiform Neurofibroma And/Or Progressive Optic Pathway Glioma
GOSH NHS Foundatin Trust
Great Ormond Street Hospital
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
Institution: Information not provided - US
Nadnárodní klinické studie
AUSTRÁLIE
Victoria
ADDRESS: NOT PROVIDED - AU
A phase II study of trametinib in paediatric, adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas
Institution: Information not provided - AU
FRANCIE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR